<DOC>
	<DOCNO>NCT01147731</DOCNO>
	<brief_summary>This open-label study evaluate pharmacokinetics warfarin coadministered albiglutide healthy adult subject . The primary objective ass effect albiglutide dose pharmacokinetics warfarin .</brief_summary>
	<brief_title>A Drug Interaction Study With Albiglutide Warfarin</brief_title>
	<detailed_description>This Phase I open-label study evaluate pharmacokinetics warfarin coadministered albiglutide healthy adult subject . The primary objective ass effect albiglutide dose pharmacokinetics warfarin .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>male healthy volunteer good health clinically significant disease clinically significant abnormal laboratory value body mass index ( BMI ) &gt; /=18 kg â‰¤30 kg/m2 nonsmoker positive test result hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) clinically relevant abnormality history anaphylactic reaction drug history significant cardiovascular pulmonary dysfunction history excessive bleeding current chronic history liver disease history alcohol substance abuse history thyroid disease dysfunction history gastrointestinal surgery disease history pancreatitis previously receive GLP1 mimetic compound ( e.g. , exenatide )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>albiglutide</keyword>
	<keyword>warfarin</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>